<DOC>
	<DOCNO>NCT01659281</DOCNO>
	<brief_summary>The main purpose study compare artesunate-mefloquine combination therapy give 2 3 day total dose treatment uncomplicated falciparum malaria .</brief_summary>
	<brief_title>Efficacy Artesunate-Mefloquine Combination Therapy Trat Province , Thailand</brief_title>
	<detailed_description>This randomize , open-label comparison two versus three day artesunate-mefloquine treatment patient uncomplicated falciparum malaria . Primary endpoint 63-day parasitological cure rate 2 treatment group . Secondary endpoint parasitological failure rate weekly follow-up visit Day 56 , occurence treatment-emergent adverse event day 0 , 1 2 , mefloquine blood concentration day 7 , 14 28 , vitro drug sensitivity profile parasite isolates measure inhibitory concentration . Genotyping parasite know marker drug resistence perform .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>1 . Age 5 70 year inclusive . If age &lt; 18 year subject must parent guardian attendance . 2 . Asexual stage P. falciparum parasites thick thin blood film visible plasmodial specie . 3 . Willing give inform consent . Parents guardians child adolescent must agree give informed consent . Assent necessary addition parental inform consent . 4 . Able tolerate oral therapy . 5 . Willing attend followup appointment undergo study procedure . 1 . History antimalarial drug use within past two week mefloquine ( MQ ) use within 4 week . 2 . Bleeding tendency ( history base medical record ) . 3 . Severe/complicated malaria determine investigator ( coma seizure , pulmonary edema , shock , renal failure , jaundice , severe anemia , spontaneous bleeding , hyperparasitemia ( &gt; 5 % RBCs infect ) , prostration ) . 4 . History allergy intolerance study medication . 5 . Mixed malaria infection Giemsa stain . 6 . Any condition opinion study investigator warrant parenteral antimalarial treatment . 7 . Pregnant woman nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Artesunate</keyword>
	<keyword>Mefloquine</keyword>
	<keyword>Plasmodium Falciparum</keyword>
	<keyword>Thailand</keyword>
	<keyword>Uncomplicated Plasmodium Falciparum malaria</keyword>
</DOC>